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Aim To evaluate the prognostic value of serum uric acid 
(SUA) in acute myocardial infarction (AMI) patients.
Methods Systematic review and random-effects meta-
analysis of prognostic studies assessing AMI outcomes 
(death, major adverse cardiac events, MACE) in relation to 
on-admission SUA.
Results Nine studies (7655 patients) were identified, 6 in 
the ST-segment elevation AMI patients treated with inva-
sive revascularization and three in mixed AMI type cohorts 
with variable reperfusion strategies. “High” SUA (vs “low,” 
different cut-offs) was univariately associated with high-
er short-term mortality (8 studies/6805 patients; odds ra-
tio [OR], 3.24; 95% confidence interval [CI], 2.47-4.27) and 
incidence of MACE (7/6467; OR, 2.46; 95% CI, 1.84-3.27, 
moderate heterogeneity, mild bias), and with higher me-
dium-term mortality (5/5194; OR, 2.69; 95% CI, 2.00-3.62, 
moderate heterogeneity, mild bias) and MACE (4/4299; 
OR, 1.93; 95% CI, 1.36-2.74, high heterogeneity, mild bias). 
It was independently associated with a higher short-term 
(4/3625; OR, 2.26, 95% CI, 1.85-2.77) and medium/long-
term (3/2683; hazard ratio [HR], 1.30; 95% CI 1.01-1.68, 
moderate heterogeneity, mild bias) occurrence of poor 
outcomes (death/MACE). As a continuous variable (by 50 
μmol/L), higher SUA was also independently associated 
with poorer medium/long-term outcomes (4/3533; HR, 
1.19; 95% CI, 1.03-1.37, high heterogeneity, mild bias). All 
individual study effects (unadjusted or adjusted) were in 
the same direction, but differed in size. Heterogeneity was 
mainly due to the included AMI type and/or definition of 
MACE. All bias-corrected pooled effects remained signifi-
cant.
Conclusion Based on the available data, high(er) on-ad-
mission SUA independently predicts worse short-term 
and medium/long-term outcomes after AMI. However, the 
number of data are modest and additional prospective 
studies are warranted.
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In humans, uric acid is the end product of purine metabo-
lism due to a genetically determined lack of uricase activ-
ity (1). It is generated by oxidation of xanthine, primarily 
in the liver, gut, kidneys, and apparently in the heart, but 
xanthine oxidase (XO) is a ubiquitous enzyme (2). Serum 
levels of uric acid (serum uric acid, SUA) are governed by 
its production and elimination rates (via the kidney). Con-
centrations >420 μmol/L in men and >360 μmol/L in 
women are conventionally considered to represent hype-
ruricemia, values <310 μmol/L and <250 μmol/L, respec-
tively, are considered low-normal, whereas concentrations 
in-between these limits are considered high-normal (3). 
High purine intake (eg, animal foods, herring, anchovies, 
alcohol, fructose, sweetbreads) and a number of morbid-
ity (reduced renal function, conditions with a high cellular 
turnover), pharmacological (eg, diuretics) and genetically 
determined factors (eg, urate transporter or organic anion 
transporter mutations) may contribute to development of 
high SUA (4).
Uric acid has several effects of potential interest in car-
diovascular diseases (CVD). It is a potent antioxidant but 
can also promote oxidative stress, particularly at high con-
centrations and/or in surroundings with a low pH and/or 
low levels of other antioxidants (3-5). Furthermore, in vit-
ro, it has several effects on the vascular smooth muscle 
and mononuclear cells that are considered important in 
pathophysiology of CVD (5). Consequently, high(er) SUA 
has been extensively evaluated as a prognostic factor for 
different CVDs (3-5). However, increased SUA is linked to 
various conditions that per se are CVD risk factors (eg, hy-
pertension, dyslipidemia, diabetes, metabolic syndrome, 
renal failure) and it has not been always possible to dis-
tinguish whether it is a cause or a consequence of such 
conditions (3-5). Next, in a failing heart or a hypoxic heart, 
activation of XO occurs (2,6). This inevitably results in in-
creased SUA, but XO per se promotes oxidative stress and 
endothelial dysfunction (2). Inhibition of XO re-establishes 
endothelial function, whereas lowering of SUA by uricosu-
ric agents does not seem to achieve this effect (2). Hence, 
the role of SUA in CVD has been accompanied by a contro-
versy: should it be viewed as a “true” risk factor (ie, a “direct 
pathogen”) or as a mere marker of conditions that actually 
are the risk factors (6).
Considering coronary artery disease, a recent meta-anal-
ysis of 26 large prospective cohort studies indicated an 
independent association between hyperuricemia and oc-
currence of the disease and related mortality (7). Less is 
known about SUA as a potential predictor of outcomes in 
patients affected by the acute myocardial infarction (AMI). 
By 2009, two studies indicated independent association 
between high(er) on-admission SUA and worse outcomes 
(8,9). The aim of the current study was to perform a system-
atic review and, if feasible, meta-analysis of observational 
studies in order to evaluate the prognostic value of SUA 
in this setting.
MaTerialS and MeThodS
literature search and study eligibility
We searched PubMed Medline, Ovid Medline, and Embase 
(till February 2012, no language restrictions; Web extra ma-
terial 1) and bibliographies of studies selected for full-text 
retrieval. Considered were only prognostic studies (pro-
spective or retrospective) that assessed major AMI out-
comes (death or major adverse cardiac events, MACE), ir-
respectively of the post-index event observational period, 
AMI type (with, STEMI, or without, NSTEMI, ST-segment el-
evation), and treatment strategy, specifically in relation to 
on-admission SUA.
Study selection and abstracting
The two authors independently reviewed the titles, ab-
stracts, and full-text articles to decide on study inclusion 
and also abstracted the selected studies. Disagreements 
and uncertainties were resolved by a consensus.
outcomes
The outcomes of interest were mortality and incidence 
of MACE. Expectedly, definitions of MACE differed across 
studies, but always included all or most of the events such 
as re-infarction, angina, need for revascularization, cardiac 
arrest, death. Therefore, data for this composite outcome 
were used as reported. Extracted were time-to-event data, 
as well as “single time-point” data. Data were extracted for 
SUA as a continuous variable or as a categorical variable, 
eg, “high” vs “low” SUA irrespectively of the cut-off values 
used to define the categories.
data adjustments
Raw data on a previously described cohort (9) were avail-
able and were re-calculated to fit the format suitable 
for data pooling (Web extra material 2). Published data 
only were used for all other studies. Effect measures 
for SUA as a continuous variable expressed by dif-
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ferent “steps” in SUA increase (eg, by 1, 10 or 100 μmol/L 
or by 1 mg/dL) were converted to SI units (μmol/L, 1 mg/
dL = 59.48 μmol/L) and expressed per 50 μmol/L. For data 
adjustments see Web extra material 2.
data pooling and statistical analysis
Outcomes reported at individual time points were grouped 
into two time intervals after AMI. The short-term interval 
referred to the in-hospital period or, if data not available, 
to the first 30 days after AMI (in-hospital data were pre-
ferred assuming greater reliability). Medium-term interval 
referred to the outcomes reported at 1 year after AMI, or 
alternatively at 6 months to two years after AMI. Pooled es-
timates were generated for unadjusted and independent 
(from multivariate analysis) SUA effects for each outcome/
time interval available from ≥3 studies. Estimation of un-
adjusted effects of “high” vs “low” SUA was based on re-
ported frequencies. Since some studies were declared as 
retrospective and some as prospective, both odds ratios 
(OR) and risk ratios (RR) were calculated. Estimation of the 
effects of SUA as a continuous variable and estimation of 
all independent effects was based on ln(OR). For the time-
to-event data, pooled estimates were obtained only for in-
dependent effects based on ln(hazard ratio, HR). Consid-
ering the differences in evaluated settings (STEMI/NSTEMI 
patients combined, only STEMI patients, different reperfu-
sion strategies, different covariate adjustments), random-
effects (DerSimonian-Laird) meta-analysis was performed. 
Since the number of studies was small, for assessment of 
bias we combined visual inspection of the funnel plots, po-
sition of the 95% confidence intervals around the intercept 
in Egger’s regression and Duval and Tweedie’s trim and fill 
method. Heterogeneity (based on I2 and Q test) was ex-
plored only in relation to categorical moderators. Mixed-
effect approach was used to analyze the subsets and to 
generate the across-subset estimates. We used CMA soft-
ware version 2.2 (Biostat Inc., Englewood, NJ, USA).
reSulTS
Characteristics of the selected studies
Of the 391 identified individual study reports, 14 studies 
were retrieved in full text and 9 (7655 patients) met the 
inclusion criteria (Figure 1, Table 1, descriptions in the 
Web extra material 1). Three studies included mixed STE-
MI/NSTEMI cohorts with variable reperfusion strategies 
(8,9,14), whereas six studies included exclusively STE-
MI patients who underwent primary percutaneous 
coronary intervention (PCI) (10-13,15,16) (Table 1). The re-
ported outcomes were short-term (in-hospital, 30-day) or 
medium/long-term outcomes with variably long follow-
up periods (Table 1). In all studies and for all reported out-
comes, high(er) on-admission SUA was univariately associ-
ated with worse results (Table 2). All studies reported also 
on independent associations between SUA and at least 
one of the assessed outcomes (Table 2) (Web extra mate-
rial 1 for multivariate models). High(er) SUA was indepen-
dently associated with worse outcomes in all studies (Ta-
ble 2). In one study (12), it was independently associated 
with higher in-hospital incidence of MACE but not with in-
hospital mortality (Table 2).
Of the five excluded studies (3411 patients, Web extra ma-
terial 1), one (17) reported on a subset of patients from 
one of the included studies, another one (18) was poor 
by methodology/reporting (both indicated univariate as-
sociation between higher on-admission SUA and worse 
in-hospital AMI outcomes), one was a small randomized 
controlled trial (19) indicating beneficial effects of al-
lopurinol (an XO inhibitor) on short-term biochemical and 
electrophysiological indicators in STEMI/PCI patients, and 
two (20,21) were prognostic studies in patients undergo-
ing revascularization procedures, but only a minority were 
AMI patients. One indicated independent association of 
“high” SUA and higher long-term all-cause mortality (20), 
and the other one reported independent association of 
“high” SUA and occurrence of PCI-induced renal impair-
ment (21).
Figure 1. Study selection flow. Mi – myocardial infarction.
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Pooled estimates of univariate associations
Short-term mortality. Based on eight studies (6805 patients), 
two in mixed STEMI/NSTEMI cohorts (8,9) and six in STEMI/
PCI patients (10-13,15,16), “high” SUA was associated with 
higher mortality – OR, 3.24 (95% CI, 2.47-4.27), RR, 2.95 (95% 
CI, 2.29-3.80) – with mild heterogeneity (Figure 2) and no in-
dication of bias. After removal of the study by Akpek 2011 
(15) (low SUA cut-off, potential partial patient overlap with 
the later larger study by Kaya 2012 [16]), the effect in five 
studies in STEMI/PCI patients (OR, 2.72; 95% CI, 1.91-3.87; 
I2 = 31.9%) was somewhat lower than the effect in studies 
Table 1. general characteristics of studies (in chronological order) evaluating the prognostic value of on-admission serum uric acid 
(Sua) for outcomes of the acute myocardial infarction (aMi) included in the present analysis. For detailed descriptions, see Web extra 
material 1*
Study/type data source Patients
outcomes and analysis approach 
to medium & long-term data
Kojima et al 2005 (8)
Retrospective
Japan, multicenter, 
admission period 
2002
Consecutive AMI, type not speci-
fied; admission ≤48 h since onset; 
N = 1124; Reperfusion (likely STEMI) 
n = 943 (84%): PCI 889, 
thrombolysis 54; no reperfusion 
(some likely NSTEMI) n = 181 (16%)
Short-term: 30-d mortality and MACE (cardiac death, 
re-infarction, unstable angina, heart failure, stroke)
Medium & long-term: mortality, maximum follow-
up 699 d
Time-to-event data (proportional hazard regression)
Car&Trkulja
2009 (9)
Retrospective
Croatia, single center, 
admission period 
1996-2001
Consecutive AMI; admission ≤48 h 
since onset; N = 621, STEMI n = 481 
(77.5%), NSTEMI n = 140; Reperfu-
sion: 10% of STEMI (thrombolysis)
Short-term: in-hospital and 30-d mortality
Medium & long-term: mortality, maximum follow-
up 13 y; n = 544 who survived the first 30 d
Time-to-event data (proportional hazard regression)
Lazzeri et al
2010 (10)
Prospective
Italy, single center, 
admission period 
likely 2004-2005†
Consecutive STEMI/PCI within 12 h 
since onset, N = 466
Short-term: in-hospital mortality
Kowalczyk et al 2010 (11)
Retrospective
Poland, single center, 
admission period 
2000-2007
Consecutive STEMI/PCI (likely 
within 12 h since onset) with 
reduced renal function – either 
on admission or caused by PCI, 
N = 1015
Mortality; MACE (death, AMI, repeated PCI, CABG, 
stroke)
Short-term: in-hospital and 30-d
Medium & long term: at 1 y and remote, maximum 
follow-up 93 mo
Time-to-event data (proportional hazard regression)
Lazzeri et al 2011 (12)
Prospective
Italy, single center, 
admission period 
2005-2009†
Consecutive STEMI/PCI within 
12 h since onset, N = 856
Short-term: in-hospital mortality and MACE (pulmo-
nary edema, arrhythmia)
Basar et al 2011 (13) 
Prospective
Turkey, single center, 
admission period 
unspecified
Consecutive STEMI/PCI within 
12 h since onset, N = 185
Short-term: in-hospital mortality and MACE (death, 
AMI, repeated revascularization)
Medium & long-term: mortality at 1 y
Single time point binary data (logistic regression)
Bae et al 2011 (14)
Retrospective
South Korea, single 
center, admission 
period 2005-2008
Consecutive AMI, N = 850, STEMI 
n = 391 (46%), other not specified 
(likely NSTEMI); Reperfusion: 623 
PCI (73.3%), other not specified; 
Onset-admission time not specified
Medium & long-term: MACE (death, non-fatal AMI or 
repeated PCI), follow-up 6 mo
Time-to-event data (proportional hazard regression)
Akpek et al 2011 (15)
Retrospective
Turkey, single center, 
admission period 
2006-2010‡
Consecutive STEMI/PCI within 
6 h since onset, N = 289
Short-term: in-hospital mortality and MACE (death, 
non-fatal AMI, stent thrombosis)
Kaya et al 2012 (16)
Retrospective
Turkey, likely multi-
center,
admission period 
2003-2009‡
Consecutive STEMI/PCI likely 
within 6 or 12 h since onset, 
N = 2249
Short-term: in-hospital MACE (death, re-infarction, 
repeated PCI, stent thrombosis)
Medium & long-term: MACE (cardiovascular death§ or 
other events as above), maximum follow-up 55 mo
Single time point binary data (logistic regression)
*abbreviations: Cabg – coronary artery by-pass grafting, MaCe – major adverse cardiac events, nSTeMi – myocardial infarction without ST-segment 
elevation, PCi – percutaneous coronary intervention, STeMi – myocardial infarction with ST-segment elevation.
†Two reports by the same group stated to be completely separate cohorts.
‡Partial overlap of patients in the two reports is possible: the admission periods overlapped and the authors of the earlier smaller report (15) are 
listed among the authors of the later larger report (16).
§no description given about the methods of identification of specific cardiovascular deaths.
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Table 2. associations of on-admission serum uric acid (Sua) concentration with outcomes after acute myocardial infarction as 
reported in studies depicted in Table 1. For multivariate models in each study, see Web extra material 1*
Study Sua (μmol/l) as univariate associations (95% Ci) independent associations (95% Ci)
Kojima et al 2005 (8) Binary: “high” (4th quartile, >399, 
n = 276) vs “low” (1st quartile, <274, 
n = 274)
Continuous: by 1
30-d mortality
High 11% vs low 2%, P < 0.001
30-d MACE†
High 14% vs low 5%, P < 0.001
Mortality over 699 d
High vs low: HR, 3.716 (1.417-9.741)
Continuous: HR, 1.004 (1.002-1.006)
Car&Trkulja 2009 (9) Continuous: by 10 In-hospital mortality
RR, 1.038 (1.026-1.051)
30-d mortality
RR, 1.035 (1.024-1.047)
All-cause mortality over 13 y
HR, 1.027 (1.015-1.039)
In-hospital mortality
RR, 1.016 (1.001-1.031)
30-d mortality
RR, 1.016 (1.003-1.029)
Mortality over 13 y
HR, 1.105 (1.020-1.195)
Lazzeri et al 2010 (10) Binary: “high” (n = 100) vs “low” 
(n = 366), cut-off 387
In-hospital mortality
High 9.0% vs low 2.5%, P = 0.006
In-hospital mortality
OR, 2.02 (1.47-2.78)
Kowalczyk et al 2010 (11) Binary: “high” (n = 352) vs “low” 
(n = 663), cut-off 420
Continuous: by 100
In-hospital mortality
High 14.5% vs low 7.1%, P < 0.001
30-d mortality
High 16.9% vs low 7.7%, P < 0.001
30-d MACE†
High 19.3% vs low 9.8%, P < 0.001
All-cause mortality at 1 y
High 25.0% vs low 13.7%, P < 0.001
MACE† at 1 y
High 47.2% vs low 40.4%, P = 0.040
Mortality over 93 mo
High vs low: HR, 1.17 (1.05-1.29)
Continuous: HR, 1.08 (1.04-1.12)
Lazzeri et al 2011 (12) Continuous: by 59.48 (1 mg/dL) In-hospital mortality
OR, 1.24 (1.03-1.51)
In-hospital MACE
OR, 1.16 (1.06-1.26)
In-hospital mortality
OR, 1.02 (0.83-1.26)
In-hospital MACE
OR, 1.11 (1.01-1.21)
Basar et al 2011 (13) Binary: “high” (n = 45) vs “low” 
(n = 140), cut-off 387
Continuous: by 59.48 (1 mg/dL)
In-hospital mortality
High 6.6% vs low 2.8%, P < 0.01
In-hospital MACE†
High 11.1% vs low 5.7%, P < 0.01
All cause mortality at 1 y
High 11.1% vs low 5.7%, P < 0.01
Continuous: OR, 1.21 (1.05-1.29)
MACE† at 1 y
High 17.7% vs low 10.0%, P = 0.017
Mortality at 1 y
High vs low: OR, 1.16 (1.10-1.41)
Continuous: OR, 1.10 (1.04-1.22)
Bae et al 2011 (14) Continuous: by 59.48 (1 mg/dL)
Binary: cut-off 419, not reported 
for all‡
— MACE† over 6 mo
Continuous: HR, 1.297 (1.075-1.565)
Akpek et al 2011 (15) Binary: “high” (n = 148) vs “low” 
(n = 141), cut-off 321
In-hospital mortality
High 13.0% vs low 2.0%, P < 0.001
In-hospital MACE‡
High 26% vs low 6.0%, P < 0.001
In-hospital MACE†
OR, 2.75 (1.93-3.94)
Kaya et al 2012 (16) Binary: “high” (n = 606) vs “low” 
(n = 1643), cut off 416 for men, 356 
for women
In-hospital mortality
High 9.0% vs low 2.0%, P < 0.001
In-hospital MACE†
High 16.0% vs low 7.0%, P < 0.001
Cardiovascular mortality during 
follow-up High 10.0% vs low 4.0%, 
P < 0.001
MACE† during follow-up
High 41.0% vs low 26%, P < 0.001
In-hospital MACE†
OR, 2.03 (1.25-3.75)
MACE† during follow-up
OR, 1.64 (1.05-2.56)
*abbreviations: Ci – confidence interval, hr – hazard ratio, or – odds ratio, rr – relative risk (risk ratio).
†MaCe (major adverse cardiac events) includes death. definitions by study are depicted in Table 1.
‡Primary analysis was not in respect to “high” or “low” Sua. however, incidence of MaCe at 30 d could be derived for 749 patients classified based 
on this cut-off, and incidence of MaCe for “high” vs “low” at 6 mo could be derived for all 850 patients.
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in mixed STEMI/NSTEMI cohorts (OR, 4.07; 95% CI, 2.82-5.87; 
I2 = 0.0%); between-subset Q = 2.40, df = 1, P = 0.121.
Short-term incidence of MACE. Based on seven studies 
(6467 patients), two in mixed STEMI/NSTEMI cohorts (8,14) 
and five in STEMI/PCI patients (11-13,15,16), “high” SUA was 
associated with higher incidence of MACE – OR, 2.46 (95% 
CI, 1.84-3.27), RR, 2.21 (95% CI, 1.64-2.97) – with moderate 
to high heterogeneity (Figure 2). The confidence inter-
vals around the Egger’s regression intercept (Figure 2), in-
spection of the funnel plot, and the trim and fill method 
(not shown) indicated bias, ie, “a missing study” on the left 
hand-side of the funnel plot. The bias-adjusted effect was 
not much changed: OR, 2.28 (95% CI, 1.70-3.07). When the 
study by Akpek 2011 (15) was excluded (low SUA cut-off, 
potential patient overlap), the effect in four studies in STE-
MI/PCI patients (OR, 1.98; 95% CI, 1.48-2.67; I2 = 54.7%) was 
lower than the effect in two studies in mixed STEMI/NSTE-
MI cohorts (OR, 3.08; 95% CI, 2.15-4.42; I2 = 0.0%); between-
subset Q = 3.41, df = 1, P = 0.065. Also, the effect in three 
STEMI/PCI studies in which MACE included death (OR, 2.35; 
95% CI, 1.88-2.93; I2 = 0.0%) was higher than the effect in 
the single study in which death was not included in this 
composite outcome (Figure 2) (between-subset Q = 6.37, 
df = 1, P = 0.012). The across subset (STEMI/NSTEMI, STE-
MI/PCI with death included, STEMI/PCI death not includ-
ed) effect was OR, 2.17 (95% CI, 1.85-2.55), Q = 10.9, df = 2, 
P = 0.004. Therefore, the among-study heterogeneity was 
likely attributable to the type of AMI included and (non)in-
clusion of death into the composite MACE outcome.
Medium-term mortality. Based on five studies (5194 pa-
tients), two in mixed STEMI/NSTEMI cohorts (8,9) and three 
in STEMI/PCI patients (11,13,16), “high” SUA was associated 
with higher mortality – OR, 2.69 (95% CI, 2.00-3.62); RR, 2.28 
(95% CI, 1.82-2.86) – with moderate heterogeneity (Figure 
2) and a slight indication of bias, ie, “a missing study” on the 
left hand-side of the funnel plot. The bias-adjusted effect 
was not much changed: OR, 2.40 (95% CI, 1.74-3.30). The 
effect in studies in STEMI/NSTEMI patients (OR, 3.82; 95% 
CI, 2.79-5.24; I2 = 0.0%) was significantly higher than the ef-
fect in studies in STEMI/PCI patients (OR, 2.11; 95% CI, 1.69-
2.65; I2 = 0.0%): between-subset Q = 8.99, df = 1, P = 0.003; 
pooled estimate across the subsets: OR, 2.58 (95%, 2.15-
3.09). Therefore, the among-study heterogeneity was likely 
attributable to the type of AMI included.
Medium-term incidence of MACE. Based on four studies 
(4299 patients), one in a mixed STEMI/NSTEMI cohort (14) 
and three in STEMI/PCI patients (11,13,16), “high” SUA was as-
sociated with higher incidence of MACE – OR, 1.93 (95% CI, 
1.36-2.74); RR, 1.62 (95% CI, 1.20-2.19) – with high heteroge-
neity (Figure 2) and a slight indication of bias, ie, “a missing 
study” on the left hand-side of the funnel plot. The bias-ad-
justed effect was not much changed: OR, 1.69 (95% CI, 1.18-
2.42). The effect in studies in STEMI/PCI patients was lower 
(OR, 1.68; 95% CI, 1.18-2.41) than the effect in the single 
study in STEMI/NSTEMI patients (Figure 2) (between-subset 
Q = 3.83, df = 1, P = 0.050), but among-study heterogeneity in 
the STEMI/PCI studies was also considerable (I2 = 71.0%).
Pooled estimates of independent associations
Short-term outcomes (in-hospital). Based on four stud-
ies (3625 patients), one in a mixed STEMI/NSTEMI cohort 
(9) and three in STEMI/PCI patients (10,15,16), “high” SUA 
was independently associated with higher incidence of 
adverse outcomes (death or MACE including death) – OR, 
2.26 (95% CI, 1.85-2.77) – with no heterogeneity (Figure 
3) and no indication of bias. The estimate was not much 
changed after removal of the study by Akpek 2011 (15) 
(low SUA cut-off, potential patient overlap): OR, 2.06 (95% 
CI, 1.61-2.64); I2 = 0.0%.
Medium & long-term outcomes (as time-to-event). Based 
on four studies (3533 patients), three in mixed STEMI/
NSTEMI cohorts (8,9,14) and one in STEMI/PCI patients (11), 
higher SUA (by 50 μmol/L) was independently associated 
with higher mortality – HR, 1.19 (95% CI, 1.03-1.37) – with 
high heterogeneity (Figure 3) and bias, ie, two “missing 
studies” on the left hand-side of the funnel plot. The bias-
adjusted effect was not much changed: HR, 1.15 (95% CI, 
1.01-1.32). The effect in studies in STEMI/NSTEMI patients 
(HR, 1.24; 95% CI, 1.14-1.35; I2 = 3.9%) was significantly 
higher than the effect in the single study in STEMI/PCI pa-
tients (Figure 3): between-subset Q = 15.8, df = 1, P < 0.001; 
pooled estimate across the subsets: HR, 1.05 (95% CI, 1.03-
1.07). Therefore, heterogeneity among the studies was like-
ly attributable to the type of AMI included.
Based on three studies (2683 patients), two in mixed STE-
MI/NSTEMI cohorts (8,9) and one in STEMI/PCI patients 
(11), “high” SUA was independently associated with high-
er mortality – HR, 1.30 (95% CI, 1.01-1.68) – with moder-
ate heterogeneity (Figure 3). When data for Kojima 2005 
(8) were used as reported (4th vs 1st quartile patients), 
the pooled estimate was not much changed, but preci-
sion was reduced and heterogeneity increased (HR, 1.45; 
95% CI, 0.99-2.11; I2 = 69.5%). The random-effect esti-
mate adjusted for bias was reduced: HR, 1.17 (95% 
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CI, 0.93-1.48). The overall fixed-effect estimate was HR, 1.20 
(95%, 1.09-1.32) and was not much changed when adjust-
ed for bias: HR, 1.17 (95%, 1.06-1.29). The effect in two stud-
ies in STEMI/NSTEMI patients (OR, 1.53; 95% CI, 1.10-2.13; 
I2 = 19.7%) was somewhat greater than the effect in the sin-
gle study in STEMI/PCI patients (Figure 3).
diSCuSSion
The role of SUA as a potential risk predictor of outcomes in 
AMI has been more closely investigated only recently: 8/9 
studies identified in the present thorough literature search 
were published within the last three years. Although the 
Figure 2. random-effects meta-analysis of unadjusted (univariate) effects of on-admission serum uric acid (Sua) on different outcomes after acute myo-
cardial infarction (aMi). The effects are expressed as a contrast between “high” (above a defined cut-off value, in μmol/l) and “low” (below the cut-off) 
Sua. asterisk represents original cohort data recalculated (see text and Web extra material 1). dagger indicates when death is included. M – men, F – 
women, STeMi – aMi with ST-segment elevation, nSTeMi – aMi without ST-segment elevation, PCi – percutaneous coronary intervention.
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overall number of patients was reasonably large, the pres-
ent results should be viewed in the light of the limitations 
of individual studies and the fact that estimates based on 
a small number of studies could be compromised by het-
erogeneity and/or bias, particularly in non-randomized 
settings.
Main findings
Based on the agreement of univariate and independent 
associations indicated by the pooled estimates (and in-
dividual studies), the present data suggest that high on-
admission SUA predicts higher short-term and medium/
long-term mortality and incidence of MACE in AMI pa-
tients. “High” SUA appears to be in the range of hyperurice-
mia or high-normal values.
limitations of the individual studies
Most of the studies (6/9) were retrospective, and hence in-
herently susceptible to bias. Still, in the case of AMI, this 
limitation might not be particularly relevant as the condi-
tion is handled after pre-defined protocols with patient 
monitoring and accurate (real-time) data recording as a 
part of the good clinical practice standard, particularly con-
sidering short(er) time-periods (eg, during in-hospital stay). 
It is reasonable to expect susceptibility to bias/inaccura-
cy to increase with longer observational periods. All stud-
ies that reported on outcomes over periods longer than 
30-day (8,9,11,13,14,16) were retrospective. However, two 
were based on databases generated prospectively after a 
pre-defined strategy (8,14), whereas methods implement-
ed in the others (9,11,13,16) convincingly suggested a rea-
sonably accurate identification of events and their timing. 
Hence, it seems plausible to consider individual study data 
as acceptably reliable.
No study matched the “high” and “low” SUA patients in re-
spect to the major AMI outcome risk factors (eg, age, Kil-
lip class, or renal function) suggested by the established 
risk stratification systems (eg 22,23, ). Hence, although 
most of the multivariate models were quite complex, im-
portant effects or effect modifiers might have been oc-
casionally omitted. While it seems unlikely that this fact 
could have resulted in misinterpretation of “no effect” 
or a “favorable effect” of high SUA as an “adverse effect” 
(particularly considering the qualitative agreement be-
tween univariate and multivariate estimates), it might 
have troubled the attempts to accurately quantify the 
true effect of high SUA.
Figure 3. random-effects meta-analysis of independent effects of on-admission serum uric acid (Sua) on different outcomes after acute myocardial in-
farction (aMi). The effects are expressed as a contrast between “high” (above a defined cut-off value, in μmol/l) and “low” (below the cut-off) Sua, or by 
50 μmol/l increase in Sua concentrations. asterisk indicates original cohort data recalculated (see text and Web extra material 1). M – men, F – women, 
STeMi – aMi with ST-segment elevation, nSTeMi – aMi without ST-segment elevation, PCi – percutaneous coronary intervention.
CLINICAL SCIENCE170 Croat Med J. 2012;53:162-72
www.cmj.hr
Strengths and limitations of the pooled analysis
The present literature search (no language or publication 
year restrictions) most likely omitted no relevant publica-
tion. The decision to exclude four of the identified prog-
nostic studies was justified as they clearly referred to pa-
tients embraced in other included reports (17), were so 
poor in respect to reporting/methodology (18) that it was 
unclear whether they indeed dealt with the topic of in-
terest, or included only sporadic AMI patients (20,21). The 
variability of the study particulars (AMI type/treatment, 
definition of MACE, consideration of SUA, follow-up dura-
tion, timing of the outcome assessment) further restricted 
the number of studies eligible for pooled analysis per out-
come/time-period, particularly in the case of independent 
associations. We therefore addressed the issue of bias and, 
within the limitations of the available methodology, dem-
onstrated that the observed SUA effects were not artifacts. 
Considering the methodological differences between 
studies (including differences in multivariate models), we 
a priori considered that no common effect size should be 
assumed and applied the random-effects meta-analysis. 
Still, for the short-term and simply defined outcomes, het-
erogeneity was non-existing or low and it increased when 
the composite outcome with variable definitions (MACE) 
or medium/long-term periods were considered. It should 
be noted, however, that heterogeneity was not due to es-
sentially different study results (all individual unadjusted or 
adjusted estimates were in the same direction), but rather 
to the differences in size of the high(er) SUA effect. The un-
dertaken exploration of heterogeneity should be viewed 
with caution, given the limited number of studies, but it 
indicates the disease/treatment characteristics (STEMI/PCI 
vs mixed STEMI/NSTEMI patients with variable reperfusion 
strategies) as its main source. Overall, the concordant pri-
mary random-effect and across-subset mixed-effect esti-
mates provide evidence of an independent association of 
high(er) on-admission SUA and worse AMI outcomes that 
may vary in strength across the disease/treatment charac-
teristics and the observed post-AMI period.
Some of the individual studies indicated that the effect 
of high SUA on medium/long-term outcomes was con-
ditional on Killip class (more pronounced in patients with 
Killip class III/IV) (8), age (more pronounced in patients 
<63 years of age) (9), or on the levels of N-terminal pro-B-
type natriuretic peptide (14) (more pronounced at high-
er concentrations). Since not based on the individual 
patient data, the present analysis could not address 
these issues.
Practical relevance of the present observations
Considering that the individual studies were conducted 
in different settings reflecting daily situations and in dif-
ferent parts of the world that could differ in genetic/cul-
tural factors affecting SUA (eg, nutritional habits, alcohol 
consumption, cigarette smoking), the present analysis 
supports a view about a robust association between the 
high(er) on-admission SUA and poor AMI outcomes. This 
observation has two potential practically relevant implica-
tions. First, it suggests that on-admission SUA should be 
considered in the risk stratification in AMI patients. In this 
respect, it should be noted that the independent effects of 
SUA (high-normal or hyperuricemic values) on short-term 
adverse outcomes are comparable in size to the effects of 
age >65 years, Killip class>II/III, or renal insufficiency, which 
are among the most important individual elements in the 
established risk stratification systems in AMI (22,23). Next, 
regardless of the known controversy about the mechanis-
tic relationship between SUA and cardiovascular outcomes 
(a “direct pathogen” or a “mere marker” of the increased XO 
activity) (2-6), high on-admission SUA might depict situa-
tions that could benefit from XO inhibition. The results of 
a small placebo-controlled trial (19) showing beneficial 
short-term effect of allopurinol in STEMI/PCI patients sup-
port such a view.
Conclusions
Over the past few years, several studies have evaluated the 
predictive value of on-admission SUA for the outcomes in 
AMI patients. Although still modest in number, the avail-
able data suggest that on-admission SUA in the high-nor-
mal or hyperuricemic range independently predicts worse 
short-term and medium/long-term outcomes. Addition-
ally, preferably prospective studies are needed to more 
precisely quantify the relationship between SUA and the 
outcomes in different settings (eg, AMI type, reperfusion 
strategies) and to characterize the seemingly complex rela-
tionships between high SUA and other predictors.
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